<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3398">
  <stage>Registered</stage>
  <submitdate>13/12/2011</submitdate>
  <approvaldate>13/12/2011</approvaldate>
  <nctid>NCT01493206</nctid>
  <trial_identification>
    <studytitle>A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer</studytitle>
    <scientifictitle>A Prospective Single Arm Study of Intraoperative Radiotherapy for Locally Advanced or Recurrent Rectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PMCC04/16</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malignant Rectal Neoplasm</healthcondition>
    <healthcondition>Recurrent Tumor</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - intraoperative radiotherapy

Experimental: intraoperative radiotherapy - 


Treatment: other: intraoperative radiotherapy
intraoperative radiotherapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>clinical outcomes - locoregional control, progression-free and overall survival rates.</outcome>
      <timepoint>3-year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>toxicities - Toxicity score criteria defined by Intraoperative Radiation Therapy Working Group Criteria</outcome>
      <timepoint>3-6 monthly up to 30 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  locally advanced or recurrent rectal cancer

          -  suitable for radical surgery but at high risk of positive resection margins,

          -  no evidence of metastasis,

          -  age greater than 18 years,

          -  histologically confirmed adenocarcinoma,

          -  ECOG performance status &lt;2.

          -  Informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  unresectable pelvic disease

          -  distant metastasis

          -  significant co-morbidities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>8006 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The hypothesis is that intraoperative radiotherapy for locally advanced or recurrent rectal
      cancer improve outcomes without causing significant side effects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01493206</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sam Ngan</name>
      <address>Peter MacCallum Cancer Centre, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>